Should I buy Biogen shares?

Biogen shares are in the limelight. The stock rallied earlier this week but have I missed my opportunity to invest in the biotech firm?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Biogen (NASDAQ: BIIB) shares are receiving a lot of attention. The stock rallied on Monday after the US Food and Drug Administration (FDA) gave approval for the company’s Alzheimer’s drug.

I’m not surprised that Biogen shares soared on this news. But should I buy now? No, but I’ll be monitoring the stock. There’s a lot of hype now surrounding this biotech firm. Firstly, I’m waiting for this euphoria to subside. Secondly, I’ve analysed the FDA’s statement, and the company still has a lot of work to do. Unfortunately, the approval isn’t straightforward.

The approval

Let me start by saying that it’s always a big deal for a biotech company when a regulator, like the FDA, gives an approval. And this certainly applies for Biogen. 

Should you invest £1,000 in Ishares Public Limited Company - Ishares Core Ftse 100 Ucits Etf right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Ishares Public Limited Company - Ishares Core Ftse 100 Ucits Etf made the list?

See the 6 stocks

Biogen has developed an Alzheimer’s drug called aducanumab, which is sold under the brand name Aduhelm. On Monday, the FDA gave this drug an accelerated approval. But what does this mean?

Well, the FDA has indicated that the drug could provide a clinical benefit to Alzheimer’s patients. But I think the key thing to note is that the FDA now requires Biogen to conduct new randomised and controlled clinical trials to verify this.

I reckon the hard work for the company has just started. If the additional trials fail to confirm clinical benefit, then the FDA may have to withdraw the approval of the drug. There’s no guarantee the drug will be successful. Now that Biogen shares have rallied and are trading close to all-time highs, the stock is likely to be sensitive to any negative news.

The opportunity

If the biotech firm can get this right, then the upside is huge. According to the FDA’s website, Alzheimer’s is a debilitating disease that affects 6.2m Americans. It’s a progressive brain disorder that slowly attacks the memory and thinking skills. Eventually, it can impair the ability to carry out simple tasks.

Now here’s where Aduhelm comes in. So far the drug is the first of its kind approved for this devastating illness. In fact, scientists have been trying for years to treat the disease. This approval is the first new treatment approved for Alzheimer’s since 2003. In my opinion, this is a crucial inflection point for the battle against the illness.

But as I mentioned, Biogen has to conduct further trials. This will come at an additional cost to the firm, which could place pressure on profitability.

Market consensus

Just as Biogen shares rallied, institutional investors have also become bullish on the stock. Several investment banks have increased their price targets.

For example, Barclays has hiked its price target for Biogen to $395 from $265, but still maintains an ‘equal weight’ rating on the stock. Citigroup has upgraded the shares from a ‘sell’ to a ‘neutral’ and lifted its target from $200 to $440.

My view

I think Biogen has made a huge amount of progress to develop a treatment to tackle Alzheimer’s. And for this I commend the biotech company.

But there’s still a lot of risk involved and no guarantee the drug will be successful in future trials. So for now, I’ll be watching the stock closely.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Ishares Public Limited Company - Ishares Core Ftse 100 Ucits Etf right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Ishares Public Limited Company - Ishares Core Ftse 100 Ucits Etf made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Nadia Yaqub has no position in any of the shares mentioned. The Motley Fool UK has recommended Barclays and Biogen. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man smiling and working on laptop
Investing Articles

3 FTSE 250 shares with low P/E ratios and sky-high dividend yields!

Searching for the best bargains that London has to offer? Here's a handful from the FTSE 250 I think are…

Read more »

Investing Articles

Why is Apple stock lagging the S&P 500 in 2025?

Our writer is wondering whether now might be an opportune time to snap up shares of the largest company in…

Read more »

Investing Articles

Here’s how an ISA investor could build a £20k passive income with UK shares

Looking to make a five-figure passive income in retirement? Here's how a blend of UK shares and cash savings could…

Read more »

Investing Articles

£10,000 in savings? Here’s how an investor can target £3,560 in annual passive income

Paul Summers explains how an investor could target making thousands of pounds in passive income by holding great dividend stocks…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Up 490%, Lion Finance Group is a new name on the FTSE 250… but what is it?

Many investors won’t be familiar with Lion Finance Group, but the FTSE 250 stock has surged 490% over five years.…

Read more »

Growth Shares

I think this is the most punished FTSE stock in the market right now

Jon Smith talks through a FTSE company that has endured problems but is one he believes has a brighter future…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Stock market correction! 1 growth share down 53% to consider buying now

This writer highlights a growth stock that has hit a rough patch in recent weeks. Here's why it might be…

Read more »

Investing Articles

Here’s why the Tesco share price has dropped 18% in a month!

Tesco's share price has lost nearly a fifth of its value since mid-February. Is this FTSE 100 dividend stock now…

Read more »